Glaucoma: An Open-Window to Neurodegeneration and Neuroprotection

by Nucci; Cerulli; Osborne; Bagetta

• ISBN13: 9780444532565
• ISBN10: 0444532560
• Edition: 1st
• Format: Hardcover
• Copyright: 2008-11-21
• Publisher: Elsevier Science

Summary

Glaucoma, one of the leading causes of blindness worldwide, is characterized by death of retinal ganglion cells (RGCs) associated with loss of optic nerve fibers and degeneration in central relays of the visual system.

Table of Contents

List of contributors	p. v
Preface	p. xi
Epidemiology and Clinical Assessment of the Disease
Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects	p. 3
Predictive models to estimate the risk of glaucoma development and progression	p. 15
Intraocular pressure and central corneal thickness	p. 25
Angle-closure: risk factors, diagnosis and treatment	p. 31
Early diagnosis in glaucoma	p. 47
Monitoring glaucoma progression	p. 59
Anatomical and Functional Monitoring
Standard automated perimetry and algorithms for monitoring glaucoma progression	p. 77
Short-wavelength automated perimetry and frequency-doubling technology perimetry in glaucoma	p. 101
Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma	p. 125
The role of OCT in glaucoma management	p. 139
Functional laser Doppler flowmetry of the optic nerve: physiological aspects and clinical applications	p. 149
Advances in neuroimaging of the visual pathways and their use in glaucoma	p. 165
Current Therapy
Primary open angle glaucoma: an overview on medical therapy	p. 181
The treatment of normal-tension glaucoma	p. 195
The management of exfoliative glaucoma	p. 211
Laser therapies for glaucoma: new frontiers	p. 225
Modulation of wound healing during and after glaucoma surgery	p. 237
Surgical alternative to trabeculectomy	p. 255
Modern aqueous shunt implantation: future challenges	p. 263
Experimental Approaches to Model Disease
Model systems for experimental studies: retinal ganglion cells in culture	p. 279
Rat models for glaucoma research	p. 285
Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection	p. 303
Clinical trials in neuroprotection	p. 323
Neuroprotection: New Vistas in Pathophysiology
Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria	p. 339
Astrocytes in glaucomatous optic neuropathy	p. 353
Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation	p. 375
Oxidative stress and glaucoma: injury in the anterior segment of the eye	p. 385
TNF-[alpha] signaling in glaucomatous neurodegeneration	p. 409
Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death	p. 423
Assessment of neuroprotection in the retina with DARC	p. 437
Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection	p. 451
Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration	p. 465
Changes of central visual receptive fields in experimental glaucoma	p. 479
Neuroprotection: Evidence for Future Strategies
Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma	p. 495
Stem cells for neuroprotection in glaucoma	p. 511
The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells	p. 521
Evidence of the neuroprotective role of citicoline in glaucoma patients	p. 541
Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon	p. 555
Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection	p. 575
17[beta]-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat	p. 583
Subject Index	p. 591
Table of Contents provided by Ingram. All Rights Reserved.